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1Abstract: The management of drug–drug interactions (DDIs) is a critical issue resulting from the overwhelming amount of information available on them. 
Natural Language Processing (NLP) techniques can provide an interesting way to reduce the time spent by healthcare professionals on reviewing 
biomedical litera-ture. However, NLP techniques rely mostly on the availability of the annotated corpora. While there are several annotated corpora with 
biological entities and their relationships, there is a lack of corpora anno-tated with pharmacological substances and DDIs. Moreover, other works in this 
field have focused in pharmacokinetic (PK) DDIs only, but not in pharmacodynamic (PD) DDIs. To address this problem, we have created a manually 
annotated corpus consisting of 792 texts selected from the DrugBank database and other 233 Medline abstracts. This fined-grained corpus has been 
annotated with a total of 18,502 pharma
the annotation process has been ensured
agreement between two anno-tators. Th
database (0.55–0.72). The DDI corpus ha
extraction techniques applied to the rec-
attracted wide attention with a total of 1
best system achieved an F1 of 71.5%, whi
has enough quality to be used for train
guidelines are free for use for academic re Information extraction
al substances and 5028 DDIs, including both PK as well as PD interactions. The quality and consistency of 
 the creation of annotation guide-lines and has been evaluated by the measurement of the inter-annotator 
ment was almost perfect (Kappa up to 0.96 and generally over 0.80), except for the DDIs in the MedLine 
 used in the SemEval 2013 DDIExtraction challenge as a gold standard for the evaluation of information 
n of pharmacological substances and the detection of DDIs from biomedical texts. DDIExtraction 2013 has 
s from 7 different countries. For the task of rec-ognition and classification of pharmacological names, the 
he detection and classification of DDIs, the best result was F1 of 65.1%. These results show that the cor-pus 
 testing NLP techniques applied to the field of Pharma-covigilance. The DDI corpus and the annotation 
and are available at http://labda.inf.uc3m.es/ddicorpus.1. Introduction
Motivated by the information explosion in Biomedicine, over
the last decade there has been a surge of interest in using Natural 
Language Processing (NLP) techniques to retrieve and extract infor-
mation from biomedical texts [1]. Most of these techniques rely 
heavily on annotated corpora to learn models that can be used to 
extract information from raw text. Annotated corpora are valuable 
resources as they provide a gold standard data for the repeatable 
automatic training and evaluation of NLP techniques [2]. Most re-
cent research has centered on biological entities and their relation-
ships (such as gene and protein interactions) mainly as a result ofthe availability of annotated corpora in the biological domain (see 
Section 2).
Other biomedical domains such as Pharmacovigilance (the sci-
ence concerned with the prevention of adverse drug reactions) can 
benefit from NLP techniques. This is the case of drug–drug 
interactions (DDIs), which are a common adverse drug reactions 
having a significant impact on patient safety and healthcare costs 
[3,4]. Although there is a large quantity of drug databases and semi-
structured resources (such as DrugBank [5], Stockley [6] or Drug 
Interactions Facts [7], among others) to assist healthcare pro-
fessionals avoid DDIs, the quality of these databases is very uneven 
and the consistency of their content is limited, so it is very difficult 
to assign a real clinical significance to each interaction [8,9]. On the 
other hand, despite the availability of these databases, a large 
amount of the most current and valuable information is unstruc-
tured, written in natural language and hidden in published articles, 
scientific journals, books and technical reports [3]. Only in the
bibliographic database MedLine, the number of published re-
searches is increased between 10,000 and 20,000 articles per week 
[10]. Therefore, researchers and healthcare professionals must re-
view a large number of drug safety reports as well as publications 
in the fields of medicine and pharmacology in order to be kept up-
to-date with everything published about DDIs. Several published 
drug safety studies have shown that DDIs may be detected too late, 
when millions of patients have already been exposed [11]. There-
fore, the management of DDIs is a critical issue as a result of the 
overwhelming amount of information available on them [12]. Thus, 
the development of automatic methods for collecting, main-taining 
and interpreting the information about drugs is crucial to achieving 
a real improvement in the early detection of DDIs.
In this paper, we describe the construction of a gold standard 
corpus, called the DDI corpus, which is annotated with pharmaco-
logical substances as well as the interactions between them. The 
DDI corpus is the first corpus which includes pharmacodynamic 
(PD) and pharmacokinetic (PK) DDIs. A PD DDI occurs when the 
pharmacological effects of one drug are modified by the presence of 
another drug, while a PK DDI is the result from the interference of 
drug absorption, distribution, metabolism and/or elimination of a 
drug by another drug. While there are several annotated corpora 
with biological entities and their relationships (see Section 2), the 
shortage of annotated corpora for DDI extraction is the main bot-
tleneck in the development of NLP systems for this area of 
Pharmacovigilance.
The DDI corpus has been developed for the DDI Extraction 2013 
challenge (http://www.cs.york.ac.uk/semeval-2013/task9/), whose 
main goal is to provide a common framework for the evaluation of 
information extraction techniques applied to the recognition of 
pharmacological substances and the detection of DDIs from bio-
medical texts. For this purpose, two substasks have been proposed: 
the recognition and classification of drug names and the extraction 
and classification of their interactions. A detailed description of the 
task, the participant teams, the results and the evaluation metrics 
can be found in [13].Table 1
Size of the biomedical corpora annotated with drugs.
Corpus Type of document Size Drugs DDIs
EU-ADR 300 1753
ADE 4272 5063
ITI TXM 400 18,000
PK-DDI 68 3986 592
PK 428 1333
CLEF
MedLine abstract 
MedLine sentences 
Full articles
Drug package inserts 
MedLine abstract 
Patient records 150 1972. Related work
The identification of drug names is a preliminary and crucial 
step in many text mining tasks such as the detection of the out-
break of diseases [14], the extraction of medication-related infor-
mation [15], the detection of adverse-drug events [16] or the 
extraction of relationships such as drug-disease [17], drug-gene 
interactions [18], DDIs [19], among many others. In fact, several 
corpora have been built for these purposes in recent years. Here, we 
review the main corpora annotated with drug entities, giving a 
special focus on those corpora that also contain DDIs.
Since each corpus has been developed for a specific task, the 
definition of the drug entity varies significantly from corpus to cor-
pus. Thus, for example, in Clinical E-Science Framework (CLEF) [20] 
and BioText [21] corpora, drug names and therapeutic devices or 
interventions are annotated with the same entity type. Other cor-
pora such as ADE (Adverse Drug Effect) [22], EU-ADR (Exploring 
and Understanding Adverse Drug Reactions) [2] or ITI TXM (Tissue 
Expressions and Protein–Protein Interactions) [23] use a single en-
tity type to annotate both drugs and chemicals, while the BioCaster 
[14] corpus distinguishes between substances for the treatment of 
diseases and chemicals not intended for therapeutic purposes. Cor-
pora such as PK-DDI (Pharmacokinetic drug–drug interaction) [24] 
or that developed by Rubrichi and Quaglini [25] propose a more 
fine-grained classification of pharmacological substances. The 
annotation schema of the PK-DDI corpus describes three types of 
entity to annotate pharmacological substances: ACTIVE INGREDI-
ENT, DRUG PRODUCT and METABOLITE. Similarly, Rubrichi et al.,propose three different entity types: ACTIVE DRUG INGREDIENT, 
DRUG or DRUG CLASS. In the PK corpus [26], drug names and 
metabolites are automatically annotated using a dictionary from 
the DrugBank database, and later manually reviewed.
To the best of our knowledge, the only two works that have ad-
dressed the annotation of DDIs are the PK-DDI corpus and the PK 
corpus. These are the closest works to ours, but differ from it in 
the scope of the annotated DDIs. While these corpora only contain 
PK DDIs, the DDI corpus also includes PD DDIs.
As regards the type of document, almost all of the aforemen-
tioned corpora are made up of MedLine abstracts (BioText, ADE, 
EU-ADR, and PK), while full articles have been used only in the 
ITI TXM corpora. Other corpora focus on the annotation of clinical 
texts such as discharge summaries [27], patient records [20] or 
clinical notes [28]. Both the PK-DDI corpus and that developed 
by Rubrichi et al., consist of texts taken from drug package inserts, 
which are one of the most important sources of information for 
healthcare professionals and patients on the use of medicines.
Table 1 shows the size of the aforesaid corpora. As regards the 
number of drug entities, the ITI TXM corpus is the largest corpora 
with almost 18,000 drug compounds, followed by the PK-DDI cor-
pus. The PK-DDI corpus was annotated with a total of 3551 active 
ingredients, 234 drug products and 201 metabolites. Only the PK 
and PK-DDI corpus contain DDIs. The size of the different corpora 
of MedLine abstracts never exceeds 500 abstracts.
Although almost all of the aforementioned corpora were cre-
ated in accordance with a set of guidelines, only a small number of 
corpora have published their guidelines. Similarly, only some 
corpora provide inter-annotator agreement scores. In general, the 
consistency in the annotation of drug entities is high (greater than 
75%), while IAA scores reported in the PK-DDI corpus (around 60%) 
suggest that annotation of DDIs is a more complex task than simply 
the identification of drug names.
3. Methods
A previous version of the DDI corpus was created for the DDIEx-
traction 2011 challenge [29]. The goal of this task was to promote 
research and provide a common framework for comparing the lat-
est advances in Information Extraction techniques applied to the 
extraction of DDIs from biomedical texts. This earlier version of the 
DDI corpus consisted of 579 documents describing drug inter-
actions that were taken from the DrugBank database. The docu-
ments were parsed using the Unified Medical Language System 
(UMLS) MetaMap Transfer tool (MMTx) [30] to automatically rec-
ognize drugs. Then, a pharmacist manually annotated the DDIs in 
texts. The main limitations of this previous version were (1) drugs 
were automatically annotated without any manual intervention in 
the process, (2) no guidelines were produced, (3) the annotation 
was carried out by a single annotator, and (4) the quality of the cor-
pus was not evaluated because the inter-agreement annotator was 
not measured.
In the current new version, we have made several improve-
ments. First of all, two experts and two text miners with back-
ground in pharmacovigilance participated in the annotation task2
(see Section 3.3). Annotation guidelines were produced and inter-
annotator agreement (IAA), a measure of the agreement between 
annotators annotating the same recording, was measured in order 
to assess the level of difficulty of the annotation task as well as the 
quality of the corpus. Another significant improvement was the 
addition of MedLine abstracts to the DDI corpus.
3.1. Building the corpus
As pointed out in Section 3, the DDI corpus is made up of texts 
from two different sources: documents describing DDIs from the 
DrugBank database (DDI-DrugBank corpus) and MedLine abstracts 
(DDI-MedLine corpus). The size of the previous version of the DDI 
corpus was increased with 213 new texts from DrugBank (which 
are added to the 579 existing documents) and with 233 MedLine 
abstracts. Therefore, the whole DDI corpus consists of 1,025 docu-
ments. A detailed description of the method used to collect the 
documents for the DDI-DrugBank corpus can be found in [19]. Doc-
ument selection for the DDI-MedLine corpus was carried out 
against PubMed. An initial set of documents was selected from 
PubMed using a query with ‘‘drug interactions’’ as Medical Subject 
Headings (MeSH) Terms. This query returned 116,919 citations 
(published between 1975 and 2011) of which 233 documents were 
randomly selected for annotation (documents without an abstract 
section were ruled out).
The MMTx [30] tool was used to analyze the documents in the 
corpus both syntactically and semantically. The basic function of 
this program is to map text to concepts in the UMLS Metathesau-
rus. This mapping between texts and UMLS concepts enables enti-
ties to be pre-annotated automatically. A more detailed description 
of this process can be found in [29].
The DDI corpus is distributed in XML documents following the 
format proposed by Pyysalo et al. [31], in order to unify the differ-
ent formats of the main corpora for protein–protein interaction 
extraction. Our main goal is to guarantee high corpus usage and 
to encourage groups studying PPI extraction to adapt their systems 
to the problem of DDI extraction. This shared format follows the 
standoff annotation principle in which the original sentence text 
is preserved and all entities are stored as offsets (see Fig. 1).
3.2. Annotation guidelines
Our annotation guidelines provide clear and accurate defini-
tions for all those entities and relationships described in the anno-
tation schema (see the Graphical Abstract). This document also 
contains the rules and conventions on how the annotation task 
should be carried out as well as providing examples clarifying their 
use. Moreover, during the annotation process different linguistic 
phenomena affecting the annotation of drug names arose. Also the 
annotation of relationships between these drugs was affected by 
syntactic aspects. All of them are collected in the annotation 
guidelines and have been reviewed in [32].
Four entity types were proposed to annotate pharmacological 
substances: drug, brand, group and drug_n. The drug type is used 
to annotate those human medicines known by a generic name,Fig. 1. A fragment from twhereas those drugs described by a trade or brand name are anno-
tated as brand entities. A drug medication frequently has several 
brand names since different companies can market it. The use of a 
brand-name drug instead of its generic name may be related to a 
higher risk of adverse drug events [33,34]. The use of either gen-
eric or brand names depends on the drug information source. Thus, 
while generic names are used in medical and pharmacological 
textbooks as well as scientific medical journals, brand names are to 
be used in drug product labels.
Since the descriptions of DDIs involving groups of drugs are very 
common in texts, our annotators decided to include the group type 
to annotate groups of drugs. Extrapolating from drug interac-tions 
involving a specific compound to interactions involving its group is 
a common procedure in some DDI information sources. However 
some authors have established that this procedure is wrong 
because this generalization is not true for all drugs [35,36]. The last 
entity type, drug_n, refers to those active sub-stances not approved 
for human use, such as, and among others, toxins or pesticides. This 
type was included because interactions between drugs and 
substances not approved for human use are fre-quently reported in 
Medline documents.
As regards the relationships, four different types of DDI 
rela-tionships are proposed:
 mechanism: This type is used to annotate DDIs that are
described by their PK mechanism (e.g. Grepafloxacin may inhibit
the metabolism of theobromine).
 effect: This type is used to annotate DDIs describing an effect
(e.g. In uninfected volunteers, 46% developed rash while receiving 
SUSTIVA and clarithromycin) or a PD mechanism (e.g. Chlorthali-
done may potentiate the action of other antihypertensive drugs).
 advice: This type is used when a recommendation or advice
regarding a drug interaction is given (e.g. UROXATRAL should
not be used in combination with other alpha-blockers).
 int: This type is used when a DDI appears in the text without
providing any additional information (e.g. The interaction of 
omeprazole and ketoconazole has been established).
Figs. 2 and 3 show sentences describing DDIs. In Fig. 2, the first 
sentence describes two interactions: effect and mechanism, and the 
last one also describes a DDI of effect type. In Fig. 3, DDIs of ef-fect 
type are described between fenfluramine and a group of drugs, 
antihypertensive drugs, as well as with some of its members (gua-
nethidine, methyldopa, reserpine). The last sentence gives an advice 
to avoid a DDI.
The proposed classification of DDIs is consistent with the infor-
mation requirements established by pharmacology experts for an 
appropriate management of DDIs in the clinical setting [35,36]. For 
this purpose, healthcare professionals must be provided with 
information on how the interaction occurs (mechanism), what 
consequences can be expected (effect) and how it can be managed 
to avoid or reduce the associated risk (advice).
Furthermore, this classification is useful to reflect the type of 
information provided from different sources. Thus, drug product 
labels provide little advice on how to minimize the risk of anhe annotated corpus.
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Fig. 2. Examples of DDIs: effect and mechanism.
Fig. 3. Examples of DDIs: effect and advice.interaction, whereas PK descriptions are very common in these 
documents [35]. On the other hand, DDI compendia (such as 
Stockley’s drug interactions [6] or Drug Interaction Facts [7]) also 
contain considerable information on advice regarding drug 
interactions.
In summary, the annotation guidelines provide detailed defini-
tions and examples of what substances and interactions should be 
annotated and which ones should not. For example metabolites and 
excipients should be annotated as drug_n entities, while drug-
protein interactions or endogenous substances should not be 
included in the annotation. Additionally the annotation guide-lines 
contain rules to deal with the annotation of specific linguistic 
phenomena such as discontinuous names, abbreviations, nested 
named entities, synonyms, adjectives, hypernymic propositions, 
and interacting entities. The annotation guidelines can be found at: 
http://labda.inf.uc3m.es/ddicorpus.Table 2
Numbers of the annotated entities in the DDI corpus.
DDI-DrugBank DDI-MedLine Total
DRUG 9901 (63%) 1745 (63%) 11,646 (63%)
BRAND 1824 (12%) 42 (1.5%) 1866 (10%)
GROUP 3901 (25%) 324 (12%) 4225 (23%)
DRUG_N 130 (1%) 635 (23%) 765 (4%)
TOTAL 15,756 2746 18,5023.3. Annotating the corpus
This section describes the process followed in the annotation of 
drugs and their interactions in the DDI corpus. Two expert pharma-
cists with a substantial background in Pharmacovigilance carried 
out the annotation task. The first contributed to the creation of 
annotation guidelines and marked up the whole corpus, while the 
second annotated a total of 1600 randomly selected sentences from 
the DDI-DrugBank corpus and 400 ones from the DDI-Med-Line 
corpus. A text miner with background in pharmacovigilance 
assisted annotators in technical aspects, such as the use of the 
annotation tool, and participated in the harmonization process, 
giving advice to resolve conflicting annotations between the two 
annotators after the annotation process. XML Notepad was the 
annotation tool used in the process. As explained in Section 3.1, all 
documents were pre-annotated with pharmacological sub-stance 
entities by the MetaMap tool (all entities were annotated with drug 
type). Then, the annotators manually reviewed these la-bels and 
added new ones and removed and modified (in particular the type 
of entity) when necessary. All mentions of pharmacolog-ical 
substances were annotated (even those that were not involved in a 
DDI). Finally, DDIs were manually annotated at a sentence level.
The annotation process relied on annotation guidelines. They 
were created in an iterative process. In their earliest development 
stage, the first annotator studied and annotated a set of 30 docu-
ments from DrugBank and 10 Medline abstracts. The previously 
defined annotation schema and initial annotation guidelines were 
discussed and established by a multidisciplinary team with two 
text mining experts and two pharmacists. The text mining expertschecked and reviewed those sentences containing disagreements, 
which were classified according to the main reason for discrepancy 
(e.g. missed entity annotation, partial matching, different entity 
type assigned, missed DDI annotation, different DDI type assigned). 
These cases were studied and discussed between the two annota-
tors and the two text mining experts, who helped to achieve con-
sensus on the final corpus. Changes in the corpus were made 
accordingly to the consensus-driven decisions. On the same way, 
annotation guidelines were modified to include new rules and 
examples.
3.4. Inter-annotator agreement
To assess the consistency and quality of the corpus as well as the 
complexity of the annotation task, the inter-annotator agree-ment 
was measured in terms of the standard Kappa statistic [37]. From 
each dataset, DDI-DrugBank and DDI-MedLine, a set of docu-ments 
was randomly selected and annotated by two different annotators. 
We should note that the IAA scores were measured after a rigorous 
process to define strict, comprehensive and clear guidelines. For 
this reason, IAA scores were calculated under exact match criteria, 
that is, the annotations should overlap completely. For the entities, 
their annotations should overlap completely and annotators should 
also agree on the assigned types. As regards the interactions, the 
annotators should agree in the annotation of the interacting drugs 
as well as the type assigned to the interac-tion. IAA results are 
shown in the following section.
4. Results
Based on the sentence splitting during preprocessing, the DDI-
DrugBank corpus contains 6795 sentences, and the DDI-MedLine 
corpus is made up of 2147 sentences. Table 2 shows the number 
of the named entity types annotated in each corpus. The most com-
mon type was drug (63%) in both corpora. However, the numbers 
of other types of entity differ between both sub-corpora. For exam-
ple, while the second most common type in the DDI-MedLine cor-
pus was drug-n (23%), these substances hardly ever occur in the4
Table 3
Numbers of the annotated relationships in each corpus.
DDI-DrugBank DDI-MedLine Total
EFFECT 1855 (39.4%) 214 (65.4%) 2069 (41.1%)
MECHANISM 1,539 (32.7%) 86 (26.3%) 1625 (32.3%)
ADVICE 1035 (22%) 15 (4.6%) 1050 (20.9%)
INT 272 (5.8%) 12 (3.7%) 284 (5.6%)
TOTAL 4701 327 5028
Table 5
IAA results of the annotated relationships in the DDI corpus.
DDI-DrugBank DDI-MedLine
KEFFECT 0.7525 0.5548
KMECHANISM 0.4214 0.5577
KADVICE 0.9428 0.5587
KINT 0.9558 0.7252
K 0.8385 0.6213DDI-DrugBank corpus. As regards relationships, Table 3 shows the
numbers of the annotated relationships in each corpus. Effect was
the dominant relationship found in the whole DDI corpus. Advice,
accounting for 20.9% of the whole relationship, showed an even
greater disproportion between both corpora because the ratio of
relationship being advice interactions in the DDI-DrugBank corpus
(22%) is much higher than in the DDI-Medline corpus (5%). These
results are further discussed in the next section.
Table 4 presents the results for the agreement per type of entity.
For the DDI-DrugBank corpus, IAA results show very high agree-
ment (0.95) for drug, brand and group entities compared to mod-
erate agreement for drug-n entities (0.44). For the DDI-MedLine
corpus, all types of entities show close and good IAA scores. In gen-
eral, IAA was higher for the DDI-DrugBank corpus than for the DDI-
MedLine corpus, except for the drug-n entity that exhibits greater
IAA in the DDI-MedLine corpus. The overall k per type of interac-
tion (see Table 5) is greater for the DDI-DrugBank corpus
(0.8385) than for the DDI-MedLine corpus (0.6213). The int type
exhibits the highest IAA in both corpora. While in the DDI-MedLine
corpus, the other types (effect, mechanism and advice) show very
close scores to each other (0.55), in the DDI-DrugBank corpus, the
mechanism type shows a lower agreement than the other types.
These results are further discussed in the next section.5. Discussion
Recently, there have been several attempts to build annotated
corpora of DDIs [24,26]. These corpora vary in size, type of annota-
tion and type of document.
The size of the DDI corpus is significantly larger than that of
other corpora annotated with drugs and DDIs, both in the number
of documents, as well as in the total number of annotated entities
and relationships.
The DDI corpus is made up of two different types of text: Med-
Line abstracts and documents describing DDIs from the DrugBank
database. Thus, the corpus covers two different styles of biomedi-
cal text: while the texts taken from the DrugBank database are
completely focused on the description of DDIs, the main topic of
the scientific texts would not necessarily be on DDIs. Moreover,
while abstracts are usually written in a very scientific language,
the language used in the texts from DrugBank is similar to the lan-
guage used in package inserts.
Our annotation guidelines could serve as a standard for anno-
tating drug names. Further, it is important to note that the DDI cor-
pus is the only available corpus specifically annotated with groupsTable 4
IAA results of the annotated entities in the DDI corpus.
DDI-DrugBank DDI-MedLine
KDRUG 0.9534 0.8467
KBRAND 0.9569 0.8853
KGROUP 0.9563 0.8299
KDRUG_n 0.4422 0.8122
K 0.9104 0.7962of drugs and substances not approved for human use. The PK and of
DDIs occurring through a PK mechanism. According to the authors
of the PK-DDI corpus, the vocabulary used to describe this type of
DDIs is significantly different from that used to describe PD DDIs
because they are discovered in distinct ways. In contrast to these
previous corpora, the DDI corpus is annotated with all DDIs de-
scribed in its texts, including both PK and PD DDIs. Additionally,
the proposed classification of DDIs is based on the information
requirements for the effective management of DDIs.
The different nature of the texts determines that the types of
entity and relationship have different ratios in the two subcorpora.
For example, substances not approved for human use are the sec-
ond most common type of entity in DDI-MedLine, these substances
account for only about 1 percent of the entities in the DDI-Drug-
Bank corpus. Similarly, brand drugs are about 12% of the entities
in the DDI-DrugBank corpus; however this type had the lowest fre-
quency in the DDI-MedLine corpus. These observations make sense
because MedLine abstracts usually describe results from laboratory
experiments, while DrugBank texts are mainly compiled from
repositories of drug interactions. As regards the distribution of
the relationships, the main difference between two subcorpora is
that the advice relationship is far more frequent in DDI-DrugBank
than in DDI-MedLine corpus. This is also consistent with the fact
that the texts from DrugBank seem to be aimed at health-care pro-
fessionals because these texts usually contain recommendations to
avoid any drug interactions and their side effects.
The most common type of relationship in the corpus is effect.
Thus, this corpus is annotated with a large amount of information
describing PD mechanisms and interaction effects. At the same
time, the corpus contains a lot of information on PK DDIs. However,
both DrugBank and MedLine documents in the corpus present a
low frequency of management recommendations. These results
agree with the characteristics of the main DDI information sources
[35,36].
Both the quality and consistency of the corpus were evaluated
by measuring the IAA scores, which allow the complexity of the
annotation task to be determined as well as providing insights into
the quality of the guidelines developed. Moreover, IAA also pro-
vides an upper bound on the performance of the automatic sys-
tems for the detection of pharmacological substances and the
interactions between them.
As regards the type of source, IAA was higher for the DDI-
DrugBank corpus than for the DDI-MedLine corpus in both entities
and relationships. One explanation for this is that MedLine
abstracts have far more complexity than texts from the DrugBank
database, which are usually expressed in simple sentences.
Similar to other annotated corpora [22,2], IAA scores are higher
for entities than for relationships. As regards the type of entity, the
highest IAA score is obtained for the brand type in both DDI-
DrugBank and DDI-MedLine corpora (see Table 4). This may be
because branded drug names are carefully selected by the manu-
facturer to be short, unique and easy to remember [38]. A high
level of agreement is observed for drugs and groups. High IAA
scores may indicate that these types are more clearly defined than
others in the annotation guidelines [39]. For example, our annota-
tors found the identification of experimental drugs (e.g. pempidine),5
which should be annotated as drug_n type, more difficult than the 
identification of the names referring to approved drugs or groups of 
drugs.
On the other hand, IAA results show moderate agreement for 
drug_n entities. These results can be due to the large variety of 
substances included in this type. Additionally, since some of these 
substances can be both endogenous (produced inside an organism) 
and exogenous (produced outside the body) (e.g. calcium or dopa-
mine), their recognition depends substantially on the context in 
which they appear. We should comment that the mentions of 
endogenous substances should not be annotated as pharmacologi-
cal substances. In particular, the agreement was lower for drug_n in 
the DrugBank corpus than in the DDI-MedLine. Metabolite names 
(e.g. descarboethoxyloratadine), which are very similar to drug 
names (e.g. loratadine), are very frequent in DrugBank texts. 
Annotators often have difficulty distinguishing between both types. 
Similarly another main reason for disagreement between 
annotators was the classification of substances such as vitamins 
since some of them can be considered as group of drugs (e.g. vita-
min A) while others are drugs (e.g. betacarotene). These differences 
were resolved in the harmonization process and more accurate 
explanations were included in the annotation guidelines.
In conclusion, the IAA scores show that annotation guidelines 
have been successfully developed and validated for the annotation 
of complex drug names such as stereoisomer (e.g. S-warfarin), salts 
(e.g. oxycodone hydrochloride) or nested named terms (e.g., thiazide 
diuretics). Therefore, the DDI corpus may be a valuable resource for 
developing systems for pharmacological substance recognition.
In general terms, fairly high IAA results are obtained per type of 
interaction (see Table 5). The int type presents the highest IAA 
scores in both DDI-DrugBank and DDI-Medline datasets. However, 
this is the lowest common type of relationship (less than 6%) anno-
tated in the corpus (see Table 3). The second DDI relationship with 
higher IAA results is the advice type. This type of DDI information is 
very clear and can be easily identified by manual annotators in both 
types of document. On the other hand, two main reasons for 
disagreement in DDI type advice have been observed. Firstly, 
annotators are frequently confused with sentences containing a 
recommendation for a specific DDI effect, as in the following sen-
tence:‘Consider additive sedative effects and confusional states to 
emerge if chlorprothixene is given with benzodiazepines or barbitu-
rates’. Similarly annotators also had problems with sentences 
describing a PK mechanism and suggesting a posology change to 
avoid undesired consequences. For example, the sentence: ‘Fenofi-
brate should be taken at least 1 h before or 4–6 h after a bile acid bind-
ing resin to avoid impeding its absorption’ was considered as advice 
by one annotator while the another one classified it as mechanism. 
As shown in Table 5, the mechanism type shows the lowest IAA 
scores in DDI-DrugBank corpus. One reason for this result is that 
annotators find it difficult to distinguish between sentences 
describing a PD mechanism or an effect. This observation led to the 
final annotation of PD interactions with the effect type.
In general, some disagreements may be because many sen-
tences provide various textual evidence of the same interaction and 
each piece of textual evidence may correspond to a different type of 
drug interaction. This is very common in complex sen-tences 
because subordinate clauses often describe different prop-erties of 
the same interaction. In these cases, the guidelines have proposed a 
priority rule to assign the type of interaction (see the guidelines 
section). However, sometimes the annotators incor-rectly applied 
this rule, and they often tended to assign the first type described in 
the sentence instead of the type according to the priority rule. On 
the other hand, the guidelines state that clauses in compound 
sentences should be considered as indepen-dent sentences, and 
thereby, annotators should annotate each of drug interactions 
described in their clauses.6. Conclusion
We describe our efforts to build a manually annotated corpus 
for DDIs in biomedical texts. To the best of our knowledge, the 
problem of producing an annotated corpus for DDI extraction has 
not been explored to the depth and extent reported in this work, 
and the resulting corpus is the most richly semantically annotated 
resource for pharmacological text processing built to date. The DDI 
corpus can encourage the NLP community to research the develop-
ment of automatic tools to support to healthcare professionals in 
the early detection of DDIs.
To ensure the quality of the corpus and the consistency of the 
annotation, we decided to focus in the fine-grained annotation de-
scribed in this paper. In view of the preliminary results obtained in 
the SemEval 2013 DDI Extraction Task, the main objective of our 
work, the creation of a gold standard for the recognition and clas-
sification of different drug names and their interactions, has been 
achieved. Once this stage has been reached, a significant challenge 
for future work is the annotation of relevant features such as drug 
dosages, time interval between administration of the drugs, and the 
mechanism and effect of an interaction. These features would be 
very useful to characterize the previously identified drug inter-
actions. In the future, we would also like to increase the size of the 
corpus using other textual sources such as package inserts, patient 
records, case studies, discharge summaries, among others. Addi-
tionally we will annotate the interactions at document level for 
capturing those interactions spanning several sentences.
The resources described in this work, including both the anno-
tated corpus and the annotation guidelines, are available from 
http://labda.inf.uc3m.es/ddicorpus.Acknowledgments
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